The challenges posed by cancer heterogeneity

Nature Biotechnology

Volumn 30, Issue 7, 2012, Pages 604-610

  Bhatia, Sangeeta ^a,b   Frangioni, John V ^c   Hoffman, Robert M ^e,f   Iafrate, A John ^d   Polyak, Kornelia ^c  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f ANTICANCER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; ANAPLASTIC LYMPHOMA KINASE; AROMASTIN; BCR ABL PROTEIN; DINACICLIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; EXEMESTANE; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; IMATINIB; JANUS KINASE 2; K RAS PROTEIN; METHIONINE C 11; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG; VELIPARIB;

BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER RESISTANCE; CANCER STEM CELL; CANCER THERAPY; CELL DIFFERENTIATION; CELL HETEROGENEITY; CELL PROLIFERATION; COPY NUMBER VARIATION; DNA METHYLATION; DNA POLYMORPHISM; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; LUNG ADENOCARCINOMA; NOTE; PRIORITY JOURNAL; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; SMALL CELL CARCINOMA; TRIPLE NEGATIVE BREAST CANCER;

CELL DIFFERENTIATION; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; GENETIC HETEROGENEITY; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84863700963     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2294     Document Type: Note

References (0)